Prevalence and Vaccination Status of Hepatitis B among HIV-Infected Patients in N’Djamena, Chad

Résumé fourni par la source

The hepatitis B virus is transmitted in the same ways as HIV. With an estimated prevalence rate of over 8% in the general population, Chad is classified as a country with a high endemicity of hepatitis B virus infection. This study examines the prevalence of HIV/HBV co-infection and hepatitis B vaccination status among individuals who underwent voluntary HIV and hepatitis B screening at three HIV treatment centers in N’Djamena, Chad. Over an eight-month period, 2210 participants were tested, of whom 133 were co-infected with HIV/HBV, representing a prevalence of 6%. The prevalence of HIV/HBV co-infection was higher among females, 9.40%, with a sex ratio (M/F) of 0.60. The prevalence of HIV/HBeAg was 1%, while that of HIV/anti-HBcAb was 2.4%, HIV/anti-HBs antibodies was 100% negative. The average age of patients was 35 years, ranging from 18 to 70 years. The most represented age group was 25 to 35 years (36.8%). None of the co-infected participants had been vaccinated against HBV. HIV/HBV co-infection is considered a significant public health problem in Chad, requiring early diagnosis through awareness and screening campaigns among the general population, thereby enabling better care for patients co-infected with HIV/HBV.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.